Adaptive Biotechnologies Corporation
ADPT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$14.79
Price-4.95%
-$0.77
1Y
Price
Market Cap
$2.257b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-30.8%
EBITDA Margin-43.5%
Net Profit Margin-22.2%
Free Cash Flow MarginRevenue
$205.216m
+14.7%
1y CAGR+3.9%
3y CAGR+7.9%
5y CAGREarnings
-$121.229m
+24.0%
1y CAGR-1.6%
3y CAGR+6.5%
5y CAGREPS
-$0.82
+24.1%
1y CAGR-0.4%
3y CAGR+7.6%
5y CAGRBook Value
$179.536m
$496.637m
Assets$317.101m
Liabilities$84.370m
DebtDebt to Assets
17.0%
-0.9x
Debt to EBITDAFree Cash Flow
-$82.808m
+16.3%
1y CAGR+24.6%
3y CAGR+23.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company